Innate Pharma (IPHA) - Total Liabilities
Based on the latest financial reports, Innate Pharma (IPHA) has total liabilities worth $84.39 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Innate Pharma to track the company's year-over-year net asset growth rate.
Innate Pharma - Total Liabilities Trend (2005–2025)
This chart illustrates how Innate Pharma's total liabilities have evolved over time, based on quarterly financial data. See Innate Pharma free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Innate Pharma Competitors by Total Liabilities
The table below lists competitors of Innate Pharma ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
OrganiGram Holdings Inc
TO:OGI
|
Canada | CA$149.50 Million |
|
Waterco Ltd
AU:WAT
|
Australia | AU$134.40 Million |
|
Syncom Formulations (India) Limited
NSE:SYNCOMF
|
India | Rs775.88 Million |
|
Husteel
KO:005010
|
Korea | ₩316.81 Billion |
|
RF Industries Ltd
NASDAQ:RFIL
|
USA | $34.79 Million |
|
Kee Tai Properties Co Ltd
TW:2538
|
Taiwan | NT$12.02 Billion |
|
Chenghe Acquisition III Co. Class A Ordinary Share
NASDAQ:CHEC
|
USA | $5.30 Million |
|
MOLECULAR PARTNERS ADS/1
F:6ML0
|
Germany | €21.77 Million |
Liability Composition Analysis (2005–2025)
This chart breaks down Innate Pharma's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Innate Pharma.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -3.89 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Innate Pharma's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Innate Pharma (2005–2025)
The table below shows the annual total liabilities of Innate Pharma from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $84.39 Million | -17.45% |
| 2024-12-31 | $102.22 Million | -22.73% |
| 2023-12-31 | $132.29 Million | -13.94% |
| 2022-12-31 | $153.71 Million | -3.96% |
| 2021-12-31 | $160.06 Million | +5.68% |
| 2020-12-31 | $151.45 Million | -17.67% |
| 2019-12-31 | $183.94 Million | -35.23% |
| 2018-12-31 | $283.98 Million | +67.97% |
| 2017-12-31 | $169.07 Million | -13.48% |
| 2016-12-31 | $195.41 Million | -16.45% |
| 2015-12-31 | $233.89 Million | +1355.98% |
| 2014-12-31 | $16.06 Million | +3.00% |
| 2013-12-31 | $15.60 Million | -37.44% |
| 2012-12-31 | $24.93 Million | -25.54% |
| 2011-12-31 | $33.48 Million | +131.02% |
| 2010-12-31 | $14.49 Million | -15.22% |
| 2009-12-31 | $17.10 Million | -12.42% |
| 2008-12-31 | $19.52 Million | +44.10% |
| 2007-12-31 | $13.55 Million | +5.13% |
| 2006-12-31 | $12.89 Million | +174.05% |
| 2005-12-31 | $4.70 Million | -- |
About Innate Pharma
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated t… Read more